Plant ID: NPO11302
Plant Latin Name: Hymenidium lindleyanum
Taxonomy Genus: Hymenidium
Taxonomy Family: Apiaceae
NCBI TaxonomyDB:
584744
Plant-of-the-World-Online:
n.a.
TSHR; | |
TDP1; PKM; HSD17B1; NOX4; ALOX15; USP2; TNKS; TNKS2; | |
ACHE; | |
CFTR; | |
GSK3B; SYK; FLT3; CDK6; CSNK2A1; | |
CA2; CA1; CA12; CA5B; CA5A; CA6; | |
AR; | |
ESR2; ESR1; | |
MAOA; PTGS2; XDH; | |
CASP1; CASP7; | |
TP53; HIF1A; | |
ABCG2; ABCC1; | |
HTT; NPC1; MAPT; THPO; TTR; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.827E-13 | 3.504E-09 | CA1, CA12, CA2, CA5A, CA5B, CA6 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.940E-12 | 3.022E-08 | CA1, CA12, CA2, CA5A, CA5B, CA6, CFTR |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.813E-10 | 3.037E-07 | CA1, CA12, CA2, CA5A, CA5B, CA6 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.468E-10 | 1.084E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.583E-09 | 1.947E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.487E-08 | 9.521E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 4.022E-08 | 2.190E-05 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.948E-08 | 3.439E-05 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, XDH |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 2.217E-07 | 8.619E-05 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.309E-06 | 3.607E-04 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.473E-06 | 3.855E-04 | AR, CA1, CA12, CA2, CA5A, CA5B, CA6, ESR1, ESR2, TNKS, TP53 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.606E-06 | 4.066E-04 | ABCG2, ACHE, CASP1, CSNK2A1, ESR1, ESR2, FLT3, HTT, MAPT, PKM, PTGS2, TP53, TTR, USP2, XDH |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.797E-06 | 4.275E-04 | AR, CYP19A1, ESR1 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.803E-06 | 4.275E-04 | CASP1, CYP1A1, HIF1A, NOX4, PKM, PTGS2, TP53 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 1.797E-06 | 4.275E-04 | GSK3B, HTT, MAPT |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.847E-06 | 4.324E-04 | MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.652E-06 | 5.828E-04 | CASP7, CFTR, GSK3B, NOX4, PKM, PTGS2, TP53, TSHR |
BP | GO:0008152; metabolic process | GO:0032270; positive regulation of cellular protein metabolic process | 4.459E-06 | 8.747E-04 | ALOX15, AR, CASP1, CASP7, ESR1, FLT3, GSK3B, MAPT, NOX4, PTGS2, SYK, THPO, TP53, XDH |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.071E-06 | 9.602E-04 | ESR1, ESR2 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.425E-05 | 2.362E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.519E-05 | 2.420E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.519E-05 | 2.420E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.892E-05 | 2.922E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 1.924E-05 | 2.951E-03 | GSK3B, HIF1A, HTT, TP53 |
BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 1.973E-05 | 3.004E-03 | CASP1, CFTR, NOX4, PTGS2, TP53 |
BP | GO:0051179; localization | GO:0060341; regulation of cellular localization | 2.323E-05 | 3.418E-03 | AR, CFTR, CSNK2A1, GSK3B, HIF1A, HTT, MAPT, PTGS2, SYK, TP53 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 2.368E-05 | 3.461E-03 | AR, CDK6, CSNK2A1, ESR1, FLT3, HIF1A, PTGS2, SYK, THPO, TSHR |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 2.764E-05 | 3.934E-03 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.034E-05 | 4.181E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.034E-05 | 4.181E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.034E-05 | 4.181E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.034E-05 | 4.181E-03 | CYP1A2, CYP3A4 |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 3.105E-05 | 4.252E-03 | CYP1B1, HIF1A, PTGS2 |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 3.472E-05 | 4.703E-03 | CYP19A1, CYP3A4, ESR1 |
BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 3.598E-05 | 4.807E-03 | CASP1, CASP7, MAPT, XDH |
MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 3.598E-05 | 4.807E-03 | AR, CSNK2A1, ESR1, GSK3B |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.741E-05 | 6.219E-03 | ABCC1, ALOX15, SYK |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 5.049E-05 | 6.544E-03 | CYP1A1, CYP3A4 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.223E-05 | 6.690E-03 | CSNK2A1, HIF1A, MAPT |
BP | GO:0065007; biological regulation | GO:0043085; positive regulation of catalytic activity | 5.683E-05 | 7.195E-03 | CASP1, CASP7, ESR1, FLT3, GSK3B, HIF1A, MAPT, NOX4, SYK, TNKS, TSHR, XDH |
BP | GO:0050896; response to stimulus | GO:0007584; response to nutrient | 7.484E-05 | 9.200E-03 | CASP1, CYP1A1, PKM, PTGS2, TP53 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.563E-05 | 9.200E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.563E-05 | 9.200E-03 | CYP1A2, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 7.563E-05 | 9.200E-03 | CA1, CA2 |
BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 8.117E-05 | 9.819E-03 | ALOX15, PTGS2, SYK |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.131E-04 | 1.225E-02 | CA5A, CA5B, CASP1, CYP1A1, CYP1B1, ESR2, GSK3B, MAOA, NOX4, PKM, TP53 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 9.661E-13 | 1.275E-10 | CA12, CA1, CA5B, CA2, CA5A, CA6 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.955E-09 | 1.950E-07 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 8.024E-08 | 3.530E-06 | HSD17B1, CYP1A1, CYP1B1, PTGS2, CYP19A1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.757E-06 | 4.639E-05 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.809E-07 | 3.237E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.343E-05 | 3.436E-04 | AR, GSK3B, CDK6, FLT3, PTGS2, HIF1A, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.411E-05 | 3.105E-04 | PKM, FLT3, TP53, HIF1A |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.985E-05 | 3.276E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.778E-05 | 3.276E-04 | CA2, CYP3A4, CFTR, ABCG2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.303E-04 | 1.323E-03 | GSK3B, TP53, ESR1, HIF1A |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.872E-04 | 2.527E-03 | PKM, MAOA, HSD17B1, CYP1A2, ALOX15, CYP1A1, PTGS2, CYP3A4, CYP19A1, XDH |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 2.249E-04 | 2.120E-03 | GSK3B, CDK6, CSNK2A1, TP53 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.488E-05 | 4.604E-04 | CYP1A2, ALOX15, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.719E-04 | 3.461E-03 | ABCC1, CDK6, CYP1B1, PTGS2, TP53 |
09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 1.235E-04 | 1.323E-03 | ABCC1, CFTR, ABCG2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 5.329E-04 | 3.702E-03 | GSK3B, ESR1, ESR2 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.945E-04 | 3.255E-03 | CYP1A2, CYP1A1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.703E-04 | 3.461E-03 | MAOA, CYP1A2, CYP3A4 |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 9.996E-04 | 5.998E-03 | GSK3B, SYK, CSNK2A1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.056E-03 | 6.059E-03 | CDK6, PKM, SYK, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 9.887E-04 | 5.998E-03 | GSK3B, AR, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 8.951E-04 | 5.908E-03 | CDK6, PTGS2, TP53 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 1.123E-03 | 6.176E-03 | SYK, CSNK2A1, PTGS2 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.710E-05 | 5.652E-04 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; ACHE; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |